

***Fsp27/CIDEC* is a CREB Target Gene Induced During Early Fasting in Liver and Regulated by Fatty Acid Oxidation Rate**

Anna Vilà-Brau¹, Ana Luísa De Sousa-Coelho¹, Joana F. Gonçalves, Diego Haro, and Pedro F. Marrero

Department of Biochemistry and Molecular Biology, School of Pharmacy and the Institute of Biomedicine of the University of Barcelona (IBUB)

Running title: *Fsp27* is induced during early fasting in liver

¹Both authors have contributed equally to this paper. Corresponding author: Pedro F. Marrero, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Barcelona, Joan XXIII s/n, E-08028 Barcelona, Spain Tel: (34) 934034500; Fax: (34) 934024520; E-mail: pedromarrero@ub.edu

The abbreviations used are: 3-hydroxybutyrate, 3-HB; CIDEC, cell death-inducing DFFA-like effector c; Cact, carnitine/acylcarnitine translocase; Cpt1a, carnitine palmitoyltransferase-1a; Cpt2, carnitine palmitoyltransferase-2; CREB, cAMP responsive element binding protein; CTB2, CREB regulated transcription coactivator 2; FAO, fatty acid oxidation; HMGCS2, hydroxymethylglutaryl CoA synthase 2; PEPCK, phosphoenolpyruvate carboxykinase; PGC1- α , peroxisome proliferator activated receptor gamma coactivator 1 α ; PPAR, peroxisome proliferator activated receptor; SIRT1, sirtuin 1; WAT, white adipose tissue.

ABSTRACT

FSP27 (CIDEC in humans) is a protein associated with lipid droplets that downregulates the fatty acid oxidation (FAO) rate when it is overexpressed. However, little is known about its physiological role in liver. Here, we show that fasting regulates liver expression of *Fsp27* in a time-dependent manner. Thus, during the initial stages of fasting a maximal induction of 800-fold was achieved, while during the later phase of fasting, *Fsp27* expression decreased. The early response to fasting can be explained by a canonical PKA-CREB-CRTC2 signaling pathway since: i) *CIDEC* expression was induced by forskolin, ii) *Fsp27* promoter activity was increased by CREB, and iii) *Fsp27* expression was upregulated in the liver of *Sirt1* knockout animals. Interestingly, pharmacological (etomoxir) or genetic (*Hmgcs2* interference) inhibition of the FAO rate increases the *in vivo* expression of *Fsp27* during fasting. Similarly, *CIDEC* expression was upregulated in HepG2 cells by either etomoxir or *HMGCS2* interference. Our data indicate that there is a kinetic mechanism of auto-regulation between short- and long-term fasting, by which free fatty acids delivered to the liver during early fasting are accumulated/exported by FSP27/CIDEC, while over longer periods of fasting they are degraded in the mitochondria through the carnitine palmitoyl transferase (CPT) system.

Introduction

During fasting, the liver adapts its metabolism to produce the glucose needed to maintain normoglycemia. Gluconeogenesis is effective when the necessary reducing power (NADH) is made available through the mitochondrial oxidation of fatty acids (1), which are mobilized from white adipose tissue (WAT) during fasting. Coupling of the two processes is based on the ability of the liver to synthesize ketone bodies, which are soluble products of the incomplete oxidation of fatty acids that may replace glucose as an energy source, but also increase the fatty acid oxidation (FAO) rate (2).

This intricate process is orchestrated by hormones like insulin, glucagon or glucocorticoids. Thus, changes in the levels of these hormones affect the gene transcription program of the liver, which can be divided into two temporally distinct phases (3). At the onset of fasting (<12-18 h), hormonal changes produce an increase in both the level and activity of the transcriptional coactivator CRTC2 (CREB-regulated transcription coactivator 2; previously TORC2), which induces an increase in the expression of hepatic gluconeogenic genes (4). With sustained fasting (>12–18 h), SIRT1 becomes activated and deacetylates CRTC2. This event allows the ubiquitination of the protein and targets it for degradation (5). The activation of SIRT1 also results in the deacetylation of the CREB target gene PGC-1 α , which is associated with an increase in the activity of this transcriptional coactivator, providing a mechanism to further amplify gluconeogenic gene expression in response to prolonged fasting (6). At the same time, fatty acids play a major role in maintaining high levels of transcription of the PPAR-responsive genes (7, 8).

The increased delivery of fatty acids to the liver is not an exclusive characteristic of fasting. A high-fat diet produces an increase in liver fatty acids that leads to steatosis, which is accompanied by the expression of proteins characteristic of lipid droplets. One of these accumulated-liver proteins is the fat-specific protein 27 (FSP27, also known as CIDEC in humans), which belongs to a family of proteins that play critical roles in controlling metabolic homeostasis (9, 10). *Fsp27* mRNA has been detected in fatty livers, where an excess of lipids accumulates and large lipid droplets are formed (11, 12). More recently, FSP27 was shown to be a direct mediator of PPAR γ -dependent hepatic steatosis (12), which suggests that expression of FSP27 may promote lipid-droplet formation in hepatocytes. Interestingly, forced expression of FSP27 in hepatocytes significantly decreased the activity of mitochondrial β -oxidation (12), while long-term intermittent fasting induces *Fsp27* in WAT (13).

In physiological conditions, FAO is mainly regulated in liver throughout the carnitine palmitoyl transferase (CPT) system (1). The mitochondrial β -oxidation of fatty acids generates the NADH and ATP needed for gluconeogenesis, and therefore it is an important process in the establishment of considerable liver glucose output during fasting. In agreement, pharmacological treatment with etomoxir, an inhibitor of CPT1 (the key-regulatory enzyme of the CPT system (14)), reduces gluconeogenesis and liver glucose output (15).

We have recently shown that downregulation of HMGCS2 (the step-limiting enzyme of ketogenesis (16) by RNAi attenuates PPAR α -dependent stimulation of the FAO rate in the HepG2 cell line (2). We found that expression of a specific shRNA *in vivo* reduced hepatic HMGCS2 activity by 50%, which correlates with a 20% decrease in liver FAO in fasted animals. In this condition, microarray analysis showed that *Fsp27/CIDECl* was one of the genes that were most upregulated by blocking ketogenesis. Therefore, we studied the expression pattern of *Fsp27* during adaptation to fasting, and noted that it was highly induced (~250-fold and ~800-fold), mainly in the early period (6 h and 15 h of fasting, respectively). Over longer periods of fasting (24 h), the expression of PPAR α target genes remained high, but the expression of *Fsp27* decreased 4-fold with respect to its levels after 15 h of fasting. Importantly, we showed that pharmacological inhibition of FAO also upregulated *Fsp27/CIDECl* in mice liver or HepG2 cells. Additionally, we have reported that this gene is sensitive to both CREB and SIRT1 activity, which could explain its induction during the early stages of fasting.

Experimental Procedures

Plasmids

For the reporter assays, *Fsp27* promoter (-2025/+18 relative to the transcription start site) was amplified by PCR from mouse genomic DNA with the oligonucleotides forward (5'-TTA**ACGCGT**CTGCAACTCATTCTGTAGCCC) and reverse (5'-TTACT**CGAGGG**CAATACCGCGTGGCCAG), and cloned in pGL3-basic vector (Promega) using the restriction sites *Mlu*I and *Xho*I respectively (in bold in the primer sequence). The mutations in the CREB-identified sequences in the mouse *Fsp27* promoter were made by site directed mutagenesis, carried out using the QuickChangeTMSite-Directed Mutagenesis commercial kit (Stratagene) following the manufacturer's instructions. The mutants were generated by point mutations replacing the original sequences TGA**CTT**CA (CRE1 site, -375/-366) and CGTCA (CRE2 half-site, -1792/-1787) by TGAGTATC (mut 1) and ATCGC (mut 2), respectively in both sense and antisense orientations. Human *HMGCS2* promoter (-1149/+28) was used as a positive control to PPAR α transactivation. Empty pGL3-basic was used as a negative control. Mouse PPAR α expression vector (pSG5-PPAR α) was a kind gift from Dr. S. Green, Macclesfield, UK. Mouse PPAR γ 2 expression vector (pSVSport-PPAR γ) was a kind gift from Dr. B. M. Spiegelman, Harvard Medical School, Boston, USA. The pcDNA3-CREB expression plasmid was subcloned from pSV-CREB in the pcDNA3 empty vector with *Xba*I/*Hind*III restriction sites. pSV-CREB and pRSV-KCREB, expressing the wild type and the dominant-negative form CREB respectively, were kindly provided by Dr. R. H. Goodman, Vollum Institute, Portland, USA.

Animal experiments

For the fasting kinetics experiment, 10-week-old C57BL/6J male mice (supplied by Charles River) were used. Mice were either fed *ad libitum* (ZT12) with a standard chow diet or fasted for 6 h (ZT18), 15 h (ZT3) or 24 h (ZT12) and sacrificed at the indicated Zeitgeber time (ZT).

For the etomoxir treatment experiment, 8-week-old C57BL/6J male mice were injected intraperitoneally with a single dose of etomoxir (50 mg/kg body weight) for 16 h. Control mice were injected with the vehicle (water). Mice were fasted for the last 6 h of treatment and then sacrificed at ZT18.

For HMGCS2 knockdown experiments, adenoviruses encoding shRNA control or shRNA *Hmgcs2* were administered to 9-week-old C57BL/6J mice by tail-vein injection (4×10^9 pfu/animal). Nine days after injection, mice were fasted for 15 h and sacrificed at ZT3 (i.e. 3 h after the onset of the 12 h light span). Blood was collected by cardiac puncture and kept on ice

until centrifugation (1,500 x g, 15 min at 4°C). The serum obtained was stored at 4°C until analysis.

Sirt1 liver-specific knockout (*Sirt1*-LKO) mice were a kind gift from Dr. L. Guarente (17). Four-month-old *Sirt1*-LKO mice and their age-matched littermate Lox controls ($Cre^{-/-}$, *Sirt1*^{fllox/fllox}) were fasted for 15 h overnight, and sacrificed at ZT3.

Glycemia was assessed in mice using an Ascencia Elite XL glucometer and strips (Bayer) to measure glucose in the blood sampled from the heart after isoflurane inhalation (anesthesia) and opening of the cardiac cavity.

Livers were extracted and used for mitochondrial protein extraction or immediately snap frozen in liquid nitrogen and stored at -80°C until analysis. All mice were housed in cages on a 12:12 h light:dark cycle at controlled temperature (25 ± 1°C). All experimental protocols with mice were performed with the approval of the animal ethics committee of the *Universitat de Barcelona*, Barcelona, Spain.

Adenoviruses generation

For the generation of adenovirus encoding shRNA *Hmgcs2*, the sequence against mouse *Hmgcs2* GGCTTCTGTTCAGTCCAGGAGGACATCAA encoded in the pGFP-V-RS-shRNA vector (Origene, GI579478) was first tested in vitro (data not shown). To construct the recombinant adenovirus, a cassette containing the U6 promoter and shRNA sequence was subcloned from pGFP-V-RS-shRNA to the pDUAL-BASIC-EGFP shuttle vector with *EcoRI* and *HindIII* restriction sites. Further adenovirus construction, purification by CsCl gradient and titration were performed by Vector Biolabs. An adenovirus encoding scrambled shRNA was used as a control.

Ketone body determination

The concentration of total ketone bodies in mice serum was determined using the Autokit Total Ketone Bodies (Wako, Germany), following the manufacturer's instructions, as described previously (2). They are expressed as mM of 3-hydroxybutyrate (3-HB).

Cell Culture and treatments

The human hepatocellular carcinoma cells HepG2 were cultured at 37°C in a humidified atmosphere containing 5% CO₂ in Eagle's Minimum Essential Medium (MEM) supplemented with 100 U/ml penicillin G, 100 µg/mL streptomycin and heat-inactivated 10% fetal bovine serum. Etomoxir, Wy14643, GW9662, forskolin and H89 were obtained from Sigma-Aldrich. Rosiglitazone was from Alexis.

siRNA transfection

HepG2 cells were seeded 24 h before transfection at a density of 4×10^5 cells/well in 6-well plates. Specific siGENOME SMARTpool against *HMGCS2* (M-010179-01) and *SIRT1* (T2004-01), and siGENOME Non-Targeting siRNA #1 (D-001210-01-05), used as a control, were purchased from Thermo Scientific Dharmacon. A concentration of 10nM was transfected with Dharmafect 4 (Thermo Scientific Dharmacon), according to the manufacturer's instructions. Cells were harvested 72 h post-transfection and successful knockdown was assessed by real-time PCR.

Mitochondria isolation

Fresh liver (~1g) was homogenized in 5 mL of homogenization buffer (250mM saccharose, 0.1mM EDTA and 5mM TrisHCl pH 7.4) using a teflon pestle. The supernatant of the centrifugation (350 x g, 10 min at 4°C) of homogenized tissue was again centrifuged at 15,000 x g for 15 min at 4°C. The resulting pellet was washed in homogenization buffer, resuspended in 2 mL of resuspension buffer (0.4mM DTT, 1.5% Triton X-100, 100mM Tris-HCl pH 8) and desalted by dialysis using a Dialysis sack, avg. width 25 mm (1.0 in), against 1:1000 dialysis solution (20mM KH_2PO_4 , 12mM EDTA). Mitochondrial protein was quantified following the Bradford reaction and stored at -80°C.

Enzymatic activity assay

The HMGCS activity determination was carried out as described previously (16). Briefly, HMGCS activity was measured as the incorporation of [^{14}C]acetyl-CoA into HMG-CoA at 30°C for 10 min. The reaction was initiated by adding 30 μg of dialyzed mitochondrial protein extract to the reaction mixture (100mM Tris-HCl, 1mM EDTA, 20 μM acetoacetyl-CoA, 200 μM and 4000 cpm/nmol [^{14}C]acetyl-CoA) in a final volume of 200 μL . After 10 min, the enzymatic reaction was stopped by adding 300 μL of 6N hydrochloric acid and the mixture was incubated for 2 h at 100°C. To determine the amount of [^{14}C]HMG-CoA formed, non-volatile radioactivity was recovered from the vials with water, diluted in Ecolite Scintillation Liquid (ICN) and counted in an automatic analyzer. HMGCS-specific activity is expressed as nmols of produced HMG-CoA per minute per mg of protein assayed.

The CPT1A activity was measured in liver extracts by subtraction of CPT2 activity from total CPT activity as previously described (18). CPT total activity determination was carried out by the forward exchange method using 1- ^3H]carnitine. In a total volume of 0.5 mL, the standard enzyme assay mixture contained 0.2 mM of 1- ^3H]carnitine (~5000 dpm/nmol), 80 μM palmitoyl-CoA, 20 mM Hepes (pH 7.0), 1% fatty acid-free albumin, and 60 mM KCl, with

(CPT2 activity) or without (total CPT activity) 50 μ M malonyl-CoA (Sigma-Aldrich), the physiological inhibitor of CPT1A activity (14). Reactions were initiated by addition of 0.1 mg of liver postnuclear extracts (see below). The reaction was linear up to 4 min, and all incubations were done at 30 °C for 3 min. Reactions were stopped by addition of 6% perchloric acid and were then centrifuged at 2300 rpm for 5 min. The resulting pellet was suspended in water, and the product [3 H]palmitoylcarnitine was extracted with butanol at low pH. After centrifugation at 3000 rpm for 3 min, an aliquot of the butanol phase was transferred to a vial for radioactive counting.

Fatty acid oxidation determination

Fatty acid oxidation was determined as previously described (19, 20). Briefly, hepatic postnuclear extracts were obtained by homogenization of ~ 20 mg of frozen tissue in 1 mL of homogenization buffer (50mM KH_2PO_4 , 150mM NaCl, 30mM EDTA, 250mM saccharose, 1mM DTT) using a Dounce homogenizer. Following centrifugation at 250 x g for 10 min at 4°C, the postnuclear supernatant was recovered and quantified by the Bradford method. Fatty acid oxidation was determined as pmols [14 C]palmitoyl-CoA oxidized per minute per mg of protein. The reaction was performed at 37°C for 11 min by adding 15 μ g of postnuclear extracts to the reaction mixture (200mM NAD^+ , 10mM FAD^+ , 1mM DTT, 75 mg/L BSA, 1mM L-carnitine, 100mM CoA, 10mM and 5000 dpm/nmol Palmitoyl Coenzyme A[Palmitoyl-1- 14 C]). The reaction was stopped by adding 7% HClO_4 and the mixture was incubated for 1 h at 4°C. Radiolabeled acid-soluble products were determined by counting the supernatant of the centrifugation (12,000 x g, 2 min, 4°C) diluted in Ecolite Scintillation Liquid (ICN) in an automatic analyzer.

Western blot analysis

Liver mitochondrial and whole cell extracts were loaded in a 10-12% SDS-PAGE gel and then transferred to Immobilon-P membranes (Millipore, Bedford, MA) and probed with different antibodies. The antibodies used were mHMGCS2 (1:1000, sc-33828) and VDAC (1:500, sc-32063) from Santa Cruz Biotechnologies, and FSP27 anti-serum [kindly provided by Dr. M. Kasuga, Japan (21)] and Tubulin (Calbiochem, CP06) for mitochondrial and whole cell extracts, respectively. Detection was carried out using an ECL Chemiluminescence Detection Kit for HRP (Biological Industries).

Real-time PCR analysis

Total RNA was extracted from HepG2 cells or liver by Tri-Reagent (Ambion) and was further treated with DNase I (Ambion). For real-time PCR analysis, cDNA was synthesized from total RNA by MLV reverse transcriptase (Invitrogen) with random hexamers (Roche Diagnostics). cDNA was subjected to real-time PCR analysis using TaqMan universal PCR master mix (Invitrogen) and the specific gene expression Taqman probes from Applied Biosystems. For HepG2 cells, the following human gene probes were used: *CIDEA* Hs00535723_m1, *HMGCS2* Hs00985427_m1, and *PEPCK* Hs00159918_m1. For mice experiments, mouse probes were used: *Cact* Mm00451571_m1, *Cpt1a* Mm00550438_m1, *Cpt2* Mm00487202_m1, *Fsp27* Mm00617672_m1, and *Hmgcs2* Mm00550050_m1. Relative mRNA abundance was obtained by normalizing to 18S levels (Applied Biosystems).

Luciferase reporter assay

HepG2 cells were seeded at a density of 1.5×10^5 cells/well in 24-well plates and transfected using Lipofectamine LTX (Invitrogen), following the manufacturer's instructions. Four hundred ng of reporter gene construct and 0.15-0.25 μ g of the eukaryotic expression vector (pcDNA3, PPAR α , PPAR γ or CREB) were co-transfected. The plasmid pRL-CMV (10 ng/well) was included as an internal transfection control. Cells were harvested after 48 h post-transfection using the passive lysis method (Promega) and luciferase assays were performed using the Dual Luciferase Reporter Assay System (Promega), following the manufacturer's recommendations. Firefly and Renilla luciferase activities were determined in a Berthold Sirius Luminometer.

Statistical Analysis

All results are expressed as means \pm SEM. Significant differences were assessed using the two-tailed Student's *t* test. $P < 0.05$ was considered statistically significant.

Results

***Fsp27* expression is induced in liver during the early steps of fasting**

Figure 1A shows that *Fsp27* is induced more than 800-fold in early fasting (15 h), but its expression is reduced during longer periods of starvation (24 h). A similar kinetic of FSP27 expression levels is observed for the protein in liver (Figure 1B). This induction is not observed during the corresponding periods of time in mice fed *ad libitum* (data not shown). These results suggest that *Fsp27* is specifically responsive to the signals that control the early fasting response, and that its expression could be attenuated when expression of genes that control fatty acid oxidation (FAO) (CPT system [*Cpt1a*, *Cact*, *Cpt2*]), ketogenesis (*Hmgcs2*) are maintained (Figure 1C), and FAO is firmly active (Figure 1D).

Downregulation of FAO increases *Fsp27/CIDEc* expression

Next, we studied whether the FAO rate affected *Fsp27/CIDEc* expression. Figure 2A shows that 10 μ M etomoxir, a CPT1 inhibitor that blocks FAO (14), induces *CIDEc* mRNA levels in HepG2 cells. Figure 2B shows that CPT1A activity was inhibited in the liver of short-term (6 h) starved animals that were i.p. injected with etomoxir. Consistently, the etomoxir treated animals were hypoglycemic (Figure 2C). In addition, the etomoxir treatment induced FSP27 expression more than 50-fold (Figure 2D). This induction correlates with an increase (more than 150-folds) of the *Fsp27* mRNA (Figure 2E). As expected, Figure 2F shows that the pharmacological treatment induced, to a lesser extent, the hepatic expression of *Cpt1a* and *Hmgcs2*, that control FAO and ketogenesis respectively (22).

Recently, we have shown that HMGCS2 also regulates the FAO rate in HepG2 cells (2). Therefore, we used the interference of HMGCS2 to downregulate FAO in HepG2 cells and mouse liver. Figure 3A (left) shows that *CIDEc* mRNA expression was induced by siRNA mediated downregulation of *HMGCS2* (right). The induction of *Fsp27* was also observed in a mouse model. Figure 3B shows that a 50% reduction in HMGCS2 activity was achieved by tail-vein injection of an adenovirus that expresses a specific shRNA for HMGCS2 (see insert of Figure 3B). As expected, the low enzymatic activity correlated with a 25% reduction in plasma ketone bodies (Figure 3C). Consistently, the interference of HMGCS2 *in vivo* produced both a 20% reduction of FAO (Figure 3D), and an increase of *Fsp27* mRNA and protein levels (Figure 3E).

Taken together, these results indicate that *Fsp27/CIDEc* expression is regulated by the FAO rate.

***Fsp27* is not a PPAR α target gene in HepG2 cells**

To investigate whether PPAR α was responsible for *Fsp27* induction during fasting, we used an *Fsp27*-promoter luciferase assay, and also studied the effect of a PPAR α synthetic ligand (Wy14643) on *CIDEA* mRNA levels in HepG2 cells. Figure 4A shows that, as expected (12), *Fsp27* is a PPAR γ target gene, although it is not activated by PPAR α in a reporter assay in which *HMGCS2* promoter (a *bona fide* PPAR α target gene (2)) was used as a control. Additionally, Figure 4B shows that a PPAR α synthetic ligand (Wy14643) was unable to induce *CIDEA* expression. To further study whether PPAR γ was involved in *Fsp27/CIDEA* expression changes affected by the FAO rate, we used a specific PPAR γ antagonist (GW9662). Figure 4C shows that although the antagonist could blunt the etomoxir effect on *PEPCK* expression, it was unable to attenuate the *CIDEA* induction mediated by etomoxir.

***Fsp27* is activated by CREB and its early induction by fasting is repressed by SIRT1**

During short-term fasting, the increase in circulating pancreatic glucagon stimulates the gluconeogenic program through the activation of the cAMP pathway, leading to the upregulation of gluconeogenic genes. Figure 5A (left) shows that forskolin, an adenylate cyclase activator, induced *CIDEA* mRNA in HepG2 cells. This induction was abolished by a PKA inhibitor (H89). Figure 5A (right) shows the expected effect of this cAMP stimulator on *PEPCK* expression. Figure 5B (left) shows that a plasmid expressing KCREB (a dominant repressor of CREB activity) could also blunt forskolin induction of the *CIDEA* endogenous gene. To understand the molecular mechanism underlying *Fsp27/CIDEA* early fasting-mediated expression in liver, we analyzed the sequence of the 5'-flanking region of the mouse *Fsp27* gene, and found two putative CREB response elements (CRE) starting at positions -1787 (CRE2) and -366 (CRE1) upstream of the transcription start site. The upstream site (CRE2) is a conserved half-site motif (CGTCA), while the downstream site (CRE1) is an eight-base-pair element (TGACTTTCA), partially conserved from the canonical palindrome (TGACGTCA). To test whether the *Fsp27* gene transcription was induced by CREB, we made several constructs with the luciferase gene as a reporter (Figure 5C, insert). We transfected HepG2 cells with these constructs and an expression vector for CREB. Figure 5C shows that CREB overexpression induced the wild type reporter, and this induction was diminished when either of the single CREs were mutated (mut 1 or mut 2), or totally abolished when both elements were simultaneously mutated (mut x2). These results identify the CRE1 and CRE2 sequences as CREB-responsive elements in the *Fsp27* mouse gene.

Once gene expression is activated, hepatic SIRT1 activity reaches maximal levels after 18 h of fasting, which promotes a switch between early and late fasting signaling programs (5). To further understand the expression of *Fsp27* during fasting, we analyzed its expression in *Sirt1* liver-specific knockout mice (*Sirt1*-LKO) (17). Figure 6A shows that after 15 h fasting *Fsp27* was induced to a higher level in the liver of *Sirt1*-LKO mice than in the wild type animals. Figure 6B shows that SIRT1 interference in HepG2 cells (2) also induced the expression of the orthologous *CIDEA* gene. This data suggests that SIRT1 activity could repress the expression of *Fsp27* during late fasting.

Taken together, these data indicate that *Fsp27* is under the control of the early fasting induction program. Indeed, during late fasting, SIRT1 expression could be involved in *FSP27* downregulation during this period and also it could be mediating the effect of FAO rate on its expression (Figure 6C).

Discussion

In this paper, we show that *Fsp27* is highly induced during early fasting (6-15 hours) (Figure 1A and 1B). It is noteworthy that *Fsp27* expression was diminished in late fasting (24 hours), while the expression of the CPT system (*Cpt1a*, *Cpt2* and *Cact*) and *Hmgcs2*, which respectively regulates FAO and ketogenesis, remained unchanged (Figure 1C). Therefore, we speculate that *Fsp27* is expressed shortly after food removal, while the program for fatty acid oxidation adaptation is still in progress (Figure 1D).

FSP27/CIDEC is a lipid droplet-associated protein, which is expressed in WAT or in steatotic liver. Therefore, our finding of hepatic fasting induction of *Fsp27* was unexpected. However, a futile cycle of triglyceride/fatty acid has been proposed in fasting (23, 24). In humans, more than 60% of the fatty acids that reach the liver during fasting are re-esterified (25, 26). Indeed, fasting in mice also leads to triglyceride accumulation in the liver. Furthermore, another member of the CIDE family, CIDEB, may be involved in the maturation of VLDL by interacting with apoB-100/-48 (27). Our data suggests that FSP27/CIDEC protein could play a role in the accumulation/export of the newly synthesized triglyceride in the early steps of the fasting adaptation process.

FSP27 expression in liver represses FAO and decreases triglyceride turnover (12, 28). Here we show that, in HepG2 cells and mouse liver, pharmacological (etomoxir, Figure 2) or genetic (RNAi for HMGCS2, Figure 3) inhibition of FAO induces *Fsp27/CIDEC* expression. These data suggest that there is a competition for free fatty acids in the liver between the systems that accumulate and store them (FSP27), and those that oxidize them (the CPT system and ketogenesis [HMGCS2]). Therefore, we propose a kinetic mechanism of auto-regulation between short- and long-term fasting, by which free fatty acids delivered to the liver during early fasting are accumulated/exported (FSP27/CIDEC), while over longer periods of fasting fatty acids are oxidized through the CPT system in the mitochondria.

We investigated whether PPAR α , a master regulator of fasting in liver, could be one of the signals that triggered the induction of *Fsp27* in fasting. However, the fasting expression pattern of *Fsp27* appears not to be related with PPAR α signaling, as the liver expression pattern of *Fsp27* is different from that of *bona fide* (*Cpt1a*, *Cact*, *Cpt2*, *Hmgcs2*) PPAR α target genes (Figure 1A and 1C). In addition, *CIDEC* endogenous expression is not stimulated by the PPAR α ligand in HepG2 cells (Figure 4B), and the *Fsp27* promoter is sensitive to PPAR γ , but not to PPAR α expression in both HEK293 (12) and HepG2 (Figure 4A) cell lines. Interestingly, a PPAR γ antagonist does not impair the stimulation by etomoxir of *CIDEC* expression (Figure

4C). Therefore, our data suggests that inhibition of FAO in liver could alter gene expression through a different mechanism from that of increased levels of free fatty acids. However, in addition to the PPAR family already studied (12), other transcription factors could be modulated by fatty acids, and we cannot completely rule out the possibility that lipid accumulation is also responsible for the *Fsp27/CIDEc* induction.

The two main intracellular signals that regulate the fasting-associated program of gene expression are cAMP and NAD⁺. SIRT1 has emerged as a protein that can interconnect both intracellular signals, since it is a NAD⁺ consuming deacetylase that was recently shown to be able to deacetylate and attenuate CREB activity (29). Interestingly, *CIDEc* gene expression was upregulated by forskolin in a hepatoma cell line (Figure 5A), and this effect was mediated by PKA and CREB (Figures 5A and 5B). Consistently, mouse *Fsp27* promoter was activated by CREB (Figure 5B) and upregulated in the liver of *Sirt1*-LKO mice (Figure 6A). Recently, it has been suggested that a switch from early gene activation *via* CRTC2 to late action of FOXO1 is critical for transcriptional regulation in fasting (5). CRTC2 is a coactivator that is responsible for CREB-mediated transcriptional activation of the hepatic gluconeogenic program (30). During prolonged fasting, CRTC2 is deacetylated by the NAD⁺ dependent enzyme SIRT1, which allows its ubiquitination and degradation in the proteasome to suppress CREB-CRTC2 signaling (5). Therefore, we propose that expression of *Fsp27* during early fasting fits the model in which CREB-mediated expression is attenuated in long fasting periods (Figure 6C).

SIRT1 regulation could also explain why *Fsp27/CIDEc* expression is induced when FAO is attenuated (Figures 2 and 3). Recently, SIRT1 has been proposed as a link between protein acetylation and metabolism (31). Thus, during fasting, oxidative metabolism (FAO and ketogenesis) may be expected to pull forward, through the NADH and ATP supply, an anabolic process like gluconeogenesis. In addition to glucose, this will in turn generate NAD⁺ and stimulate SIRT1 (an NAD⁺ consuming enzyme) activity (2). Therefore, *Fsp27/CIDEc*, a gene that is repressed by SIRT1, will be upregulated by a blunted FAO (Figure 6C).

In conclusion, here we show that a lipid droplet-associated protein, *Fsp27/CIDEc*, was expressed in liver in a physiological situation like the early stages of fasting. We also describe that *Fsp27* is a CREB target gene that is upregulated when FAO/ketogenesis is impaired, thus providing new insight in the regulation of fasting metabolism.

References

1. McGarry, J. D., and D. W. Foster. 1980. Regulation of hepatic fatty acid oxidation and ketone body production. *Annu Rev Biochem* **49**: 395-420.
2. Vilà-Brau, A., A. L. De Sousa-Coelho, C. Mayordomo, D. Haro, and P. F. Marrero. 2011. Human HMGCS2 Regulates Mitochondrial Fatty Acid Oxidation and FGF21 Expression in HepG2 Cell Line. *J Biol Chem* **286**: 20423-20430.
3. Dominy, J. E., Y. Lee, Z. Gerhart-Hines, and P. Puigserver. 2010. Nutrient-dependent regulation of PGC-1alpha's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5. *Biochim Biophys Acta* **1804**: 1676-1683.
4. Le Lay, J., G. Tuteja, P. White, R. Dhir, R. Ahima, and K. H. Kaestner. 2009. CRTC2 (TORC2) contributes to the transcriptional response to fasting in the liver but is not required for the maintenance of glucose homeostasis. *Cell Metab* **10**: 55-62.
5. Liu, Y., R. Dentin, D. Chen, S. Hedrick, K. Ravnskjaer, S. Schenk, J. Milne, D. J. Meyers, P. Cole, J. Yates, J. Olefsky, L. Guarente, and M. Montminy. 2008. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. *Nature* **456**: 269-273.
6. Altarejos, J. Y., and M. Montminy. 2011. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. *Nat Rev Mol Cell Biol* **12**: 141-151.
7. Leone, T. C., C. J. Weinheimer, and D. P. Kelly. 1999. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. *Proc Natl Acad Sci U S A* **96**: 7473-7478.
8. Sanderson, L. M., M. V. Boekschoten, B. Desvergne, M. Müller, and S. Kersten. 2010. Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. *Physiol Genomics* **41**: 42-52.
9. Gong, J., Z. Sun, and P. Li. 2009. CIDE proteins and metabolic disorders. *Curr Opin Lipidol* **20**: 121-126.
10. Puri, V., S. Konda, S. Ranjit, M. Aouadi, A. Chawla, M. Chouinard, A. Chakladar, and M. P. Czech. 2007. Fat-specific protein 27, a novel lipid droplet protein that enhances triglyceride storage. *J Biol Chem* **282**: 34213-34218.
11. Yu, S., K. Matsusue, P. Kashireddy, W. Q. Cao, V. Yeldandi, A. V. Yeldandi, M. S. Rao, F. J. Gonzalez, and J. K. Reddy. 2003. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. *J Biol Chem* **278**: 498-505.
12. Matsusue, K., T. Kusakabe, T. Noguchi, S. Takiguchi, T. Suzuki, S. Yamano, and F. J. Gonzalez. 2008. Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. *Cell Metab* **7**: 302-311.
13. Karbowska, J., and Z. Kochan. 2012. Intermittent fasting up-regulates Fsp27/Cidec gene expression in white adipose tissue. *Nutrition* **28**: 294-299.
14. Declercq, P. E., J. R. Falck, M. Kuwajima, H. Tyminski, D. W. Foster, and J. D. McGarry. 1987. Characterization of the mitochondrial carnitine palmitoyltransferase enzyme system. I. Use of inhibitors. *J Biol Chem* **262**: 9812-9821.
15. Ratheiser, K., B. Schneeweiss, W. Waldhäusl, P. Fasching, A. Korn, P. Nowotny, M. Rohac, and H. P. Wolf. 1991. Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. *Metabolism* **40**: 1185-1190.
16. Clinkenbeard, K. D., W. D. Reed, R. A. Mooney, and M. D. Lane. 1975. Intracellular localization of the 3-hydroxy-3-methylglutaryl coenzyme A cycle enzymes in liver. Separate

- cytoplasmic and mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A generating systems for cholesterologenesis and ketogenesis. *J Biol Chem* **250**: 3108-3116.
17. Chen, D., J. Bruno, E. Easlson, S. J. Lin, H. L. Cheng, F. W. Alt, and L. Guarente. 2008. Tissue-specific regulation of SIRT1 by calorie restriction. *Genes Dev* **22**: 1753-1757.
 18. Nicot, C., L. Napal, J. Relat, S. González, A. Llebaria, G. Woldegiorgis, P. F. Marrero, and D. Haro. 2004. C75 activates malonyl-CoA sensitive and insensitive components of the CPT system. *Biochem Biophys Res Commun* **325**: 660-664.
 19. Vilà, L., A. Rebollo, G. S. Adalsteisson, M. Alegret, M. Merlos, N. Roglans, and J. C. Laguna. 2011. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. *Toxicol Appl Pharmacol* **251**: 32-40.
 20. Lazarow, P. B. 1981. Assay of peroxisomal beta-oxidation of fatty acids. *Methods Enzymol* **72**: 315-319.
 21. Nishino, N., Y. Tamori, S. Tateya, T. Kawaguchi, T. Shibakusa, W. Mizunoya, K. Inoue, R. Kitazawa, S. Kitazawa, Y. Matsuki, R. Hiramatsu, S. Masubuchi, A. Omachi, K. Kimura, M. Saito, T. Amo, S. Ohta, T. Yamaguchi, T. Osumi, J. Cheng, T. Fujimoto, H. Nakao, K. Nakao, A. Aiba, H. Okamura, T. Fushiki, and M. Kasuga. 2008. FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. *J Clin Invest* **118**: 2808-2821.
 22. Hegardt, F. G., D. Serra, and G. Asins. 1995. Influence of etomoxir on the expression of several genes in liver, testis and heart. *Gen Pharmacol* **26**: 897-904.
 23. Hanson, R. W., and L. Reshef. 2003. Glyceroneogenesis revisited. *Biochimie* **85**: 1199-1205.
 24. Reshef, L., Y. Olswang, H. Cassuto, B. Blum, C. M. Croniger, S. C. Kalhan, S. M. Tilghman, and R. W. Hanson. 2003. Glyceroneogenesis and the triglyceride/fatty acid cycle. *J Biol Chem* **278**: 30413-30416.
 25. Kalhan, S. C., S. Mahajan, E. Burkett, L. Reshef, and R. W. Hanson. 2001. Glyceroneogenesis and the source of glycerol for hepatic triacylglycerol synthesis in humans. *J Biol Chem* **276**: 12928-12931.
 26. Jensen, M. D., K. Ekberg, and B. R. Landau. 2001. Lipid metabolism during fasting. *Am J Physiol Endocrinol Metab* **281**: E789-793.
 27. Ye, J., J. Z. Li, Y. Liu, X. Li, T. Yang, X. Ma, Q. Li, Z. Yao, and P. Li. 2009. Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. *Cell Metab* **9**: 177-190.
 28. Matsusue, K. 2010. A physiological role for fat specific protein 27/cell death-inducing DFF45-like effector C in adipose and liver. *Biol Pharm Bull* **33**: 346-350.
 29. Qiang, L., H. V. Lin, J. Y. Kim-Muller, C. L. Welch, W. Gu, and D. Accili. 2011. Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylation. *Cell Metab* **14**: 758-767.
 30. Koo, S. H., L. Flechner, L. Qi, X. Zhang, R. A. Screaton, S. Jeffries, S. Hedrick, W. Xu, F. Boussouar, P. Brindle, H. Takemori, and M. Montminy. 2005. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. *Nature* **437**: 1109-1111.
 31. Guarente, L. 2011. The logic linking protein acetylation and metabolism. *Cell Metab* **14**: 151-153.

Acknowledgments

This project was supported by grants BFU2007-67322/BMC (to PFM) and SAF2010-15217 (to DH) from Spain's *Ministerio de Educación y Ciencia* and by funding from the Catalan Government (*Ajut de Suport als Grups de Recerca de Catalunya* 2005SGR00857 and 2009SGR163). AVB was supported by a scholarship from the Catalan Government (*Ajut al Personal Investigador FPI* 2007-2011), ALDSC was supported by the Portuguese Government's *Fundação para a Ciência e a Tecnologia (FCT)*. We are truly grateful to Dr. Leonard Guarente and Dr. Hung-Chun Chang (Department of Biology, Massachusetts Institute of Technology, USA) for liver-specific *Sirt1* knockout mice; and to Dr. Masato Kasuga and Dr. Yoshikazu Tamori (Kobe University Graduate School of Medicine, Japan) for providing FSP27 anti-serum. We also thank Carlos Del Rosario Rabadán and Albert Pérez Martí for generating the *Fsp27* promoter construct and Western blot assistance, respectively.

Footnotes

¹ DH and PFM, unpublished data.

Figure Legends

Figure 1. Hepatic *Fsp27* expression is induced by early fasting

Mice were fed *ad libitum* (AL) or subjected to 6 h, 15 h or 24 h fasting. (A) *Fsp27*, (C) *Hmgcs2* and other fatty acid oxidation gene (*Cpt1a*, *Cact* and *Cpt2*) mRNA levels in liver. (B) Western blot analysis of liver extracts showing FSP27 protein. Tubulin was used as a control. (D) Fatty acid oxidation (FAO) flux measured *ex vivo* by incubation of liver extract with ¹⁴C-Palmitoyl-CoA, monitored by acid-soluble metabolites. Results are means ± SEM for each group (n=5 mice) **p<0.01, ***p<0.001 relative to AL; #p<0.05, ##p<0.01, ###p<0.001 relative to 6 h fasting; §§p<0.01 relative to 15 h fasting.

Figure 2. *Fsp27/CIDEc* is induced by etomoxir

(A) *CIDEc* mRNA levels in HepG2 treated with 10µM etomoxir for 6 h (mean of 3 independent experiments). C57BL/6J male animals were treated for 16 h with etomoxir and fasted for the last 6 h of treatment. (B) Liver CPT1A activity. (C) Blood glucose levels. (D) FSP27 and tubulin levels (top) and protein quantification (bottom) in 50 µg (Control) or 7.5 µg (Etomoxir) of liver postnuclear extracts. (E) Liver *Fsp27* mRNA levels. (F) Liver *Cpt1a* and *Hmgcs2* mRNA levels. Results are means of ± SEM for each group (n=4-5 mice) *p<0.05, **p<0.01, ***p<0.001 relative to Control.

Figure 3. *Fsp27/CIDEc* is induced by HMGCS2 knockdown

(A) *CIDEc* (left panel) and *HMGCS2* (right panel) mRNA levels in HepG2 cells treated with a siRNA control or siRNA of *HMGCS2* (2). C57BL/6J mice were injected through the tail vein with adenoviruses expressing either a control (shRNA control) or a specific shRNA (*Hmgcs2*). (B) Enzymatic activity in mitochondria from liver of 15 h fasted animals. The insert shows a Western blot analysis from mitochondrial protein extract for HMGCS2 and the mitochondrial marker VDAC. (C) Total ketone bodies, expressed as 3-HB, detected in serum. (D) Palmitate oxidation from mice liver extracts measured by acid-soluble metabolites. (E) *Fsp27* expression in liver. The insert shows a representative Western blot from liver extracts for FSP27 and tubulin. Results are means of ± SEM for each group (n=5 mice) *p<0.05; **p<0.01, ***p<0.001 relative to siRNA or shRNA control.

Figure 4. *Fsp27/CIDEc* is not a PPARα target gene

(A) HepG2 cells transfected for 48 h with mouse *Fsp27* promoter constructs cloned in pGL3-basic and co-transfected with pcDNA3, PPARγ or PPARα expression vectors, represented by fold activation to pcDNA3. Twenty-four hours before harvesting, cells were treated with 10µM

of PPAR γ and PPAR α ligands, rosiglitazone and Wy14643, respectively (closed bars). Human *HMGCS2* promoter co-transfected with PPAR α and treated or not with its ligand was used as a positive control. The mean of two independent experiments performed in duplicate are shown. **(B)** *CIDEc* and *HMGCS2* mRNA levels in HepG2 cells treated with a PPAR α synthetic ligand Wy14643 (10 μ M) for 24 h. **(C)** *CIDEc* and *PEPCK* mRNA levels in HepG2 cells treated with etomoxir and a PPAR γ antagonist (GW9662) (10 μ M each) for 6 h. Results are means of \pm SEM (n=3-4 independent experiments) **p<0.01, ***p<0.001 relative to control (DMSO treated cells); ##p<0.01 relative to etomoxir treated cells.

Figure 5. *Fsp27/CIDEc* is a CREB-target gene

(A) *CIDEc* (left panel) and *PEPCK* (right panel) mRNA levels in HepG2 cells pre-treated for 1 h with 50 μ M H89 (PKA inhibitor) and treated with 10 μ M forskolin (FSK) in OPTI-MEM (Invitrogen), or vehicle (DMSO) for 6 h. **(B)** *CIDEc* (left panel) and *PEPCK* (right panel) mRNA levels in HepG2 cells transfected for 48 h with pcDNA3 or KCREB, and treated with 10 μ M forskolin (FSK) or vehicle (DMSO) for the last 6 h before harvesting. Results are means of \pm SEM (n=3 independent experiments) **p<0.01, ***p<0.001 relative to control, #p<0.05, relative to FSK-treated cells transfected with empty vector; ##p<0.01 and ###p<0.001 relative to FSK-treated cells. **(C)** HepG2 cells transfected for 48 h with pGL3b (control) or mouse *Fsp27* promoter constructs cloned in pGL3-basic and co-transfected with either pcDNA3 or pcDNA3-CREB expression vectors, represented by fold activation to pcDNA3 (WT promoter construct). A scheme of the mouse *Fsp27* promoter-luciferase reporter construct is shown (shadow box indicates CRE elements, crossed shadow box indicates the construct in which CRE elements were mutated). pGL3-basic activation was subtracted from each condition. Results are means of 4 independent experiments performed in duplicate (*p<0.05, **p<0.01, ***p<0.001 relative to pcDNA3; #p<0.05, ##p<0.01 relative to CREB activation of WT promoter).

Figure 6. *Fsp27/CIDEc* is regulated by SIRT1 activity

(A) *Fsp27* mRNA levels in liver of wild type (WT) and *Sirt1*-LKO mice fasted for 15 h. Data are the mean \pm SEM (n=5-6 mice) **p<0.01 relative to WT. **(B)** *CIDEc* mRNA levels in HepG2 cells treated with a siRNA control or siRNA of *SIRT1*. Results are means of \pm SEM (n=4 independent experiments) *p<0.05 relative to control. **(C)** Schematic model of the *Fsp27/CIDEc* regulatory pathway under early fasting.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

